Взаимосвязь между ядерными рецепторами PPAR ?, ?, ? и ее роль в регуляции воспалительного ответа
Диссертация
Некоторые из синтетических агонистов PPAR уже являются действующими веществами ряда лекарств (Авандия, Актос, Трайкор, Безалип). В частности, фибраты — синтетические агонисты PPARa — используются в качестве гиполипидемических лекарств, а PPARy является мишенью такого класса гипогликемических лекарственных средств, как тиазолидиндионы, которые используются в терапии диабета 2 типа. В последнее… Читать ещё >
Содержание
- Список сокращений
- 1. Введение
- 2. Обзор литературы
- 2. 1. Место PPAR в семействе ядерных рецепторов
- 2. 1. 1. Место PPAR в классификации семейства ядерных рецепторов
- 2. 1. 2. Сходство структуры PPAR с другими ядерными рецепторами
- 2. 1. 3. PPAR — рецепторы жирных кислот, регулирующие метаболизм липидов и действие инсулина
- 2. 2. Механизмы PPAR-опосредованной регуляции транскрипции
- 2. 2. 1. Транскрипционные активности PPAR
- 2. 3. Регуляция активности PPAR через уровень их экспрессии
- 2. 4. Участие PPAR в регуляции воспалительных процессов в ЦНС
- 2. 4. 1. Терапевтические эффекты агонистов PPAR при лечении заболеваний ЦНС
- 2. 4. 2. Агонисты PPAR регулируют провоспалительные сигнальные пути, участвующие в заболеваниях ЦНС
- 2. 5. Астроциты-один из ключевых типов клеток, участвующих в воспалении
- 2. 5. 1. Фосфолипазы А
- 2. 5. 2. Циклооксигеназы и их продукты
- 2. 6. Участие PPAR в регуляции функций астроцитов
- 2. 1. Место PPAR в семействе ядерных рецепторов
Список литературы
- Sonoda, J., L. Pei, and R.M. Evans, Nuclear receptors: decoding metabolic disease. FEBS Lett, 2008. 582(1): p. 2−9.
- Szanto, A., et al., RetinoidXreceptors: X-ploring their (patho)physiological functions. Cell Death Differ, 2004. 11 Suppl 2: p. S126−43.
- Shulman, A.I. and D, J. Mangelsdorf, Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med, 2005. 353(6): p. 604−15.
- Li, Y., M.H. Lambert, and H.E. Xu, Activation of nuclear receptors: a perspective from structural genomics. Structure, 2003. 11(7): p. 741−6.
- Nagy, L. and J.W. Schwabe, Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci, 2004. 29(6): p. 317−24.
- Ни, E., et al., Inhibition of adipogenesis through MAP kinase-mediated phosphorylation ofPPARgamma. Science, 1996. 274(5295): p. 2100−3.
- A unified nomenclature system for the nuclear receptor superfamily. Cell, 1999. 97(2): p. 161−3.
- Michalik, L. and W. Wahli, PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res, 2008. 2008: p. 134 059.
- Fruchart, J.C., P. Duriez, and B. Staels, Peroxisomeproliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol, 1999. 10(3): p. 245−57.
- Harrington, W. W., et al., The Effect ofPPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice. PPAR Res, 2007. 2007: p. 97 125.
- Lehmann, J.M., et al., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem, 1995. 270(22): p. 12 953−6.
- Lefebvre, P., et al., Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest, 2006. 116(3): p. 57 180.
- Costet, P., et al., Peroxisomeproliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem, 1998. 273(45): p. 29 577−85.
- Li, A.C. and W. Palinski, Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Annu Rev Pharmacol Toxicol, 2006. 46: p. 1−39.
- Viljoen, A. and A.S. Wierzbicki, Potential options to treat hypertriglyceridaemia. Curr Drug Targets, 2009.10(4): p. 356−62.
- Smyth, S. and A. Heron, Diabetes and obesity: the twin epidemics. Nat Med, 2006.12(1): p. 75−80.
- Babaev, Y.R., et al., Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vase Biol, 2005. 25(8): p. 1647−53.
- Krall, R.L., Cardiovascular safety of rosiglitazone. Lancet, 2007. 369(9578): p. 1995−6.
- Barish, G.D., V.A. Narkar, and R.M. Evans, PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest, 2006. 116(3): p. 590−7.
- Evans, R.M., G.D. Barish, and Y.X. Wang, PPARs and the complex journey to obesity. Nat Med, 2004. 10(4): p. 355−61.
- Ricote, M. and C.K. Glass, PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta, 2007. 1771(8): p. 926−35.
- Daynes, R.A. and D.C. Jones, Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol, 2002. 2(10): p. 748−59.
- Kostadinova, R., W. Wahli, and L. Michalik, PPARs in diseases: control mechanisms of inflammation. Curr Med Chem, 2005. 12(25): p. 2995−3009.
- Devchand, P.R., et al., The PPARalpha-leukotriene B4 pathway to inflammation control Nature, 1996. 384(6604): p. 39−43.
- Delerive, P., et al., Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem, 1999. 274(45): p. 32 048−54.
- Marx, N., et al., PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation, 2001. 103(2): p. 213−9.
- Marx, N., et al., PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999. 99(24): p. 3125−31.
- Neve, B.P., et al., PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation, 2001. 103(2): p. 207−12.
- Xu, X., et al., PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells. Endocrinology, 2001. 142(8): p. 3332−9.
- Staels, В., et al., Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature, 1998. 393(6687): p. 790−3.
- Ikawa, H., et al., Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Exp Cell Res, 2001.267(1): p. 73−80.
- Ulivi, V., R. Cancedda, and F.D. Cancedda, 15-deoxy-delta 12,14-prostaglandin J (2) inhibits the synthesis of the acute phase protein SIP24 in cartilage: Involvement of COX-2 in resolution of inflammation. J Cell Physiol, 2008. 217(2): p. 433−41.
- Zhang, Q., et al., Involvement of PPARgamma in oxidative stress-mediated prostaglandin E (2) production in SZ95 human sebaceous gland cells. J Invest Dermatol, 2006. 126(1): p. 42−8.
- Pang, L., et al., Cyclooxygenase-2 expression by nonsteroidal antiinflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. J Immunol, 2003. 170(2): p. 1043−51.
- Welch, J.S., et al., PPARgamma andPPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad SciU S A, 2003.100(11): p. 6712−7.
- Glinghammar, В., et al., PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Commun, 2003. 308(2): p. 361−8.
- Kockx, M., et al., Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood, 1999. 93(9): p. 2991−8.
- Madej, A., et al., Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia lib. Int J Clin Pharmacol Ther, 1998. 36(6): p. 345−9.
- Cunard, R., et al., Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol, 2002. 168(6): p. 2795−802.
- Lovett-Racke, A.E., et al., Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol, 2004. 172(9): p. 5790−8.
- Marx, N., et al., PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res, 2002. 90(6): p. 703−10.
- Cunard, R., et al., WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J Immunol, 2002. 169(12): p. 6806−12.
- Xu, J., et al., Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. JNeurosci Res, 2005. 81(3): p. 403−11.
- Ding, G., et al., PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol, 2006. 40(6): p. 821−8.
- Kuenzli, S. and J.H. Saurat, Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study. Dermatology, 2003. 206(3): p. 252−6.
- Lee, C.H., et al., Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science, 2003. 302(5644): p. 453−7.
- Haffner, S.M., et al., Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 2002.106(6): p. 679−84.
- Setoguchi, K., et al., Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances В cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest, 2001. 108(11): p. 1667−75.
- Jiang, С., A.T. Ting, and B. Seed, PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998. 391(6662): p. 82−6.
- Ricote, M., et al., The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998. 391(6662): p. 79−82.
- Marx, N., et al., Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol, 2000.164(12): p. 6503−8.
- Murao, К., et al., Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett, 1999. 454(1−2): p. 27−30.
- Cunard, R., et al., Repression oflFN-gamma expression by peroxisome proliferator-activated receptor gamma. J Immunol, 2004. 172(12): p. 75 306.
- Yang, X.Y., et al., Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem, 2000. 275(7): p. 4541−4.
- Delerive, P., et al., Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res, 1999. 85(5): p. 394−402.
- Bensinger, S J. and P. Tontonoz, Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature, 2008. 454(7203): p. 470−7.
- Glass, C.K. and M.G. Rosenfeld, The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev, 2000. 14(2): p. 121−41.
- McKenna, N .J. and B.W. O’Malley, Combinatorial control of gene expression by nuclear receptors and coregulators. Cell, 2002. 108(4): p. 465−74.
- Rosenfeld, M.G., V.V. Lunyak, and C.K. Glass, Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev, 2006. 20(11): p. 1405−28.
- Jepsen, K., et al., Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell, 2000. 102(6): p. 753−63.
- Chen, J.D. and R.M. Evans, A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature, 1995. 377(6548): p. 454−7.
- Horlein, A. J., et al., Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature, 1995. 377(6548): p. 397−404.
- Li, J., et al., Both corepressorproteins SMRTandN-CoR exist in large protein complexes containingHDAC3. EMBO J, 2000.19(16): p. 4342−50.
- Yoon, H.G., et al., Purification andfunctional characterization of the human N-CoR complex: the roles ofHDACS, TBL1 and TBLRL EMBO J, 2003. 22(6): p. 1336−46.
- Ни, X. and M.A. Lazar, The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature, 1999. 402(6757): p. 936.
- Xu, H.E., et al., Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature, 2002. 415(6873): p. 813−7.
- Perissi, V., et al., A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell, 2004. 116(4): p. 511−26.
- Pascual, G. and C.K. Glass, Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab, 2006.17(8): p. 321−7.
- Delerive, P., et al., Induction oflkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem, 2000. 275(47): p. 367 037.
- Goetze, S., et al., PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun, 2002. 293(5): p. 1431−7.
- Paumelle, R., et al., Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase С signaling pathway. Circ Res, 2006. 98(3): p. 361−9.
- Kamei, Y., et al., А СВР integrator complex mediates transcriptional activation andAP-1 inhibition by nuclear receptors. Cell, 1996. 85(3): p. 403−14.
- Li, M., G. Pascual, and C.K. Glass, Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol, 2000. 20(13): p. 4699−707.
- Zuo, X., et al., Oxidative metabolism oflinoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene, 2006. 25(8): p. 1225−41.
- Ghisletti, S., et al., Parallel SUMOylation-dependentpathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell, 2007. 25(1): p. 57−70.
- Becker, J., et al., Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation. Pulm Pharmacol Ther, 2008. 21(2): p. 324−30.
- Necela, B.M., W. Su, and E.A. Thompson, Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor gamma and nuclear factor-kappaB in macrophages. Immunology, 2008.125(3): p. 34 458.
- Xiao, В., et al., Effect of nuclear factor-kappaB on peroxisome proliferator activated receptor gamma expression in Ana-1 cells. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2009. 21(1): p. 3−7.
- Lee, J., et al., The effect of PPARalpha and PPARgamma ligands on inflammation and ABC Al expression in cultured gallbladder epithelial cells. DigDis Sci, 2008. 53(6): p. 1707−15.
- Barish, G.D., et al., A Nuclear Receptor Atlas: macrophage activation. Mol Endocrinol, 2005.19(10): p. 2466−77.
- Huang, J.T., et al., Interleukin-4-dependentproduction of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature, 1999. 400(6742): p. 378−82.
- Harada, K., et al., Thl cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis. Hepatology, 2005. 41(6): p. 1329−38.
- Lemay, D.G. and D.H. Hwang, Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. J Lipid Res, 2006. 47(7): p. 1583−7.
- Sun, G.Y., et al., Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res, 2004. 45(2): p. 205−13.
- Lee, T.I., et al., Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors. Eur J Clin Invest, 2009. 39(1): p. 23−30.
- Li, L., et al., The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo. Cytokine, 2009. 45(1): p. 12−9.
- Leininger, M.T., C.P. Portocarrero, and K.L. Houseknecht, Peroxisome proliferator-activated receptor gammal expression in porcine white blood cells: dynamic regulation with acute endotoxemia. Biochem Biophys Res Commun, 1999. 263(3): p. 749−53.
- Inoue, H., T. Tanabe, and K. Umesono, Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem, 2000. 275(36): p. 28 028−32.
- Andersson, C., et al., Alterations in immune response andPPAR/LXR regulation in cystic fibrosis macrophages. J Cyst Fibros, 2008. 7(1): p. 6878.
- Matsusue, K., J.M. Peters, and F J. Gonzalez, PPARbeta/delta potentiates PPARgamma-stimulated adipocyte differentiation. Faseb J, 2004. 18(12): p. 1477−9.
- Babaev, V.R., et al., Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation, 2007.116(12): p. 1404−12.
- Leisewitz, A.V., et al., A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis. J Cell Physiol, 2008. 217(2): p. 367−76.
- Ogata, M., et al., On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis, 2009. 205(2): p. 413−9.
- Heneka, M.T. and G.E. Landreth, PPARs in the brain. Biochim Biophys Acta, 2007.1771(8): p. 1031−45.
- Tzeng, S.F., H.Y. Hsiao, and O.T. Мак, Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy, 2005. 4(3): p. 335−40.
- Bright, J. J., et al., PPAR Regulation of Inflammatory Signaling in CNS Diseases. PPAR Res, 2008. 2008: p. 658 520.
- Diab, A., et al., Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta (12,14)-prostaglandin J (2) ameliorates experimental autoimmune encephalomyelitis. J Immunol, 2002. 168(5): p. 2508−15.
- Feinstein, D.L., et al., Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol, 2002. 51(6): p. 694−702.
- Natarajan, C. and J J. Bright, Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Thl differentiation. Genes Immun, 2002. 3(2): p. 59−70.
- Storer, P.D., et al., Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol, 2005. 161(1−2): p. 113−22.
- Niino, M., et al., Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J Neuroimmunol, 2001. 116(1): p. 40−8.
- Schmidt, S., et al., Anti-inflammatory and antiproliferative actions of PPARgamma agonists on T lymphocytes derivedfrom MS patients. J Leukoc Biol, 2004. 75(3): p. 478−85.
- Natarajan, C., et al., Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Thl response and experimental allergic encephalomyelitis. J Immunol, 2003.171(11): p. 5743−50.
- Raikwar, H.P., et al., PPARgamma antagonists reverse the inhibition of neural antigen-specific Thl response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Deltal2,14-prostaglandin J2. J Neuroimmunol, 2006. 178(1−2): p. 76−86.
- Dasgupta, S., et al., Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol, 2007. 72(4): p. 93 446.
- Polak, P.E., et al., Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol, 2005.168(1−2): p. 65−75.
- Непека, M.T., et al., Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abetal-42 levels in APPV7171 transgenic mice. Brain, 2005. 128(Pt 6): p. 1442−53.
- Watson, G.S., et al., Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry, 2005. 13(11): p. 950−8.
- McTigue, D.M., et al., The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp Neurol, 2007. 205(2): p. 396−406.
- Besson, V.C., et al., Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett, 2005. 388(1): p. 7−12.
- Allahtavakoli, M., et al., Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke. Clin Exp Pharmacol Physiol, 2006. 33(11): p. 1052−8.
- Ou, Z., et al., Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) and 15d-prostaglandin J2--mediated protection of brain after experimental cerebral ischemia in rat. Brain Res, 2006.1096(1): p. 196−203.
- Zhao, Y., et al., The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci, 2005. 22(1): p. 278−82.
- Victor, N.A., et al., Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci, 2006. 24(6): p. 1653−63.
- Nakamura, Т., et al., Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke, 2007. 38(11): p. 3016−22.
- Collino, M., et al., Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med, 2006. 41(4): p. 579−89.
- Deplanque, D., et al., Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci, 2003. 23(15): p. 6264−71.
- Iwashita, A., et al., Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J Pharmacol Exp Ther, 2007. 320(3): p. 1087−96.
- Consilvio, С., A.M. Vincent, and E.L. Feldman, Neuroinflammation, COX-2, and ALS-a dual role? Exp Neurol, 2004. 187(1): p. 1−10.
- Khan, Т.К. and D.L. Alkon, An internally controlled peripheral biomarker for Alzheimer’s disease: Erkl and Erk2 responses to the inflammatory signal bradykinin. Proc Natl Acad Sci USA, 2006.103(35): p. 13 203−7.
- Longo, F.M. and S.M. Massa, Neuroprotective strategies in Alzheimer’s disease. NeuroRx, 2004. 1(1): p. 117−27.
- Wahner, A.D., et al., Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology, 2007. 69(19): p. 1836−42.
- Lee, B.C., et al., Peroxisome proliferator-activated receptor-gamma Prol2Alapolymorphism is associated with the susceptibility to ischemic stroke in Taeeumin classified by Sasang medicine. Neurol Res, 2007. 29 Suppl 1: p. S32−7.
- Pereira, M.P., et al., The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J Neuropathol Exp Neurol, 2005. 64(9): p. 797−805.
- Szczucinski, A. and J. Losy, Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand, 2007.115(3): p. 137−46.
- Schutz, В., et al., The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci, 2005. 25(34): p. 7805−12.
- Ramanan, S., et al., PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. Free Radic Biol Med, 2008. 45(12): p. 1695−704.
- Dehmer, Т., et al., Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa В alpha induction and block of NF kappa В and iNOS activation. J Neurochem, 2004. 88(2): p. 494−501.
- Bright, J J., et al., Expression ofIL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis. J Neuroimmunol, 1998. 82(1): p. 22−30.
- Cua, D J., et al., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature, 2003. 421(6924): p. 744−8.
- Leonard, J.P., K.E. Waldburger, and S J. Goldman, Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med, 1995. 181(1): p. 381−6.
- Trinchieri, G., S. Pflanz, and R.A. Kastelein, The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity, 2003.19(5): p. 641−4.
- Segal, B.M., B.K. Dwyer, and E.M. Shevach, An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med, 1998.187(4): p. 537−46.
- Shevach, E.M., J.T. Chang, and B.M. Segal, The critical role of IL-12 and the IL-12R beta 2 subunit in the generation of pathogenic autoreactive Thl cells. Springer Semin Immunopathol, 1999. 21(3): p. 249−62.
- Glabinsk, A.R. and R.M. Ransohoff, Targeting the chemokine system for multiple sclerosis treatment. Curr Opin Investig Drugs, 2001. 2(12): p. 1712−9.
- Muller, D.M., M.P. Pender, and J.M. Greer, Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis. Curr Drug Targets Inflamm Allergy, 2004. 3(3): p. 279−90.
- Ghosh, S., M.J. May, and E.B. Kopp, NF-kappa В andRelproteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol, 1998. 16: p. 225−60.
- Sha, W.C., Regulation of immune responses by NF-kappa B/Rel transcription factor. J Exp Med, 1998. 187(2): p. 143−6.
- Grilli, M. and M. Memo, Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochem Pharmacol, 1999. 57(1): p. 1−7.
- Mattson, M.P. and S. Camandola, NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest, 2001. 107(3): p. 247−54.
- Jacobson, N.G., et al., Interleukin 12 signaling in T helper type 1 (Thl) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med, 1995. 181(5): p. 1755−62.
- Parham, C., et al., A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbetal and a novel cytokine receptor subunit, IL-23R. J Immunol, 2002.168(11): p. 5699−708.
- Aggarwal, S., et al., Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem, 2003. 278(3): p. 1910−4.
- Bright, J.J., C. Du, and S. Sriram, Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol, 1999. 162(10): p. 6255−62.
- Natarajan, C. and J.J. Bright, Curcumin inhibits experimental allergic encephalomyelitis by blockingIL-12 signaling through Janus kinase-STAT pathway in Tlymphocytes. J Immunol, 2002. 168(12): p. 6506−13.
- Chen, Y. and R.A. Swanson, Astrocytes and brain injury. J Cereb Blood Flow Metab, 2003. 23(2): p. 137−49.
- Giulian, D., et al., Interleukin 1 of the central nervous system is produced by ameboid microglia. J Exp Med, 1986. 164(2): p. 594−604.
- Norton, W.T., et al., Quantitative aspects of reactive gliosis: a review. Neurochem Res, 1992.17(9): p. 877−85.
- Minghetti, L. and G. Levi, Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol, 1998. 54(1): p. 99−125.
- Kielian, Т., Toll-like receptors in central nervous system glial inflammation and homeostasis. J Neurosci Res, 2006. 83(5): p. 711−30.
- Kigerl, К.A., et al., Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. J Neurochem, 2007. 102(1): p. 37−50.
- Lee, S.J. and S. Lee, Toll-like receptors and inflammation in the CNS. Curr Drug Targets Inflamm Allergy, 2002.1(2): p. 181−91.
- Сергеева, М.Г. and A.T. Варфоломеева, Каскад арахидоновой кислоты. 2006, Москва: Народное образование. 255.
- Rosenberger, Т.A., et al., Rat brain arachidonic acid metabolism is increased by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide. J Neurochem, 2004. 88(5): p. 1168−78.
- Balsinde, J. and E.A. Dennis, Distinct roles in signal transduction for each of the phospholipase A2 enzymes present in P388DJ macrophages. J Biol Chem, 1996. 271(12): p. 6758−65.
- Cho, W., Structure, function, and regulation of group V phospholipase A (2). Biochim Biophys Acta, 2000.1488(1−2): p. 48−58.
- Gabryel, В., et al., Activation of cPLA2 and sPLA2 in astrocytes exposed to simulated ischemia in vitro. Cell Biol Int, 2007. 31(9): p. 958−65.
- Scholz-Pedretti, K., et al., Potentiation ofTNF-alpha-stimulatedgroup IIA phospholipase A (2) expression by peroxisome proliferator-activated receptor alpha activators in rat mesangial cells. J Am Soc Nephrol, 2002. 13(3): p. 611−20.
- Bishop-Bailey, D. and T.D. Warner, PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacinacts as a peroxisome proliferator-activated receptor-gamma antagonist. FASEB J, 2003.17(13): p. 1925−7.
- Xu, L., C. Han, and T. Wu, A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth. J Biol Chem, 2006. 281(45): p. 33 982−96.
- Hirst, W.D., et al., Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system. Mol Cell Neurosci, 1999. 13(1): p. 57−68.
- Janabi, N., Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-Delta (12,14)(12,14)-prostaglandin J (2) in activated human astrocytes, but not in human brain macrophages. J Immunol, 2002.168(9): p. 4747−55.
- Combs, C.K., et al., Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci, 2000. 20(2): p. 558−67.
- Aid, S., R. Langenbach, and F. Bosetti, Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation, 2008. 5: p. 17.
- Lim, G.P., et al., Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci, 2000. 20(15): p. 570 914.
- McGeer, P.L., M. Schulzer, and E.G. McGeer, Arthritis and antiinflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology, 1996. 47(2): p. 425−32.
- Seibert, K., et al., Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol, 1997. 400A: p. 167−70.
- Nogawa, S., et al., Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci, 1997. 17(8): p. 2746−55.
- Griffin, D.E., S.L. Wesselingh, and J.C. McArthur, Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol, 1994. 35(5): p. 592−7.
- Hurley, S.D., J.A. Olschowka, and M.K. O’Banion, Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma, 2002. 19(1): p. 1−15.
- Teismann, P., et al., Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. Proc Natl Acad Sci USA, 2003. 100(9): p. 5473−8.
- Gilroy, D.W. and P.R. Colville-Nash, New insights into the role of COX 2 in inflammation. J Mol Med, 2000. 78(3): p. 121−9.
- Gilroy, D.W., et al., Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med, 1999. 5(6): p. 698−701.
- Drew, P.D., et al., Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int, 2006. 49(2): p. 183−9.
- CulHngford, Т.Е., et al., Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J Neurochem, 1998. 70(4): p. 1366−75.
- Granneman, J., R. Skoff, and X. Yang, Member of the peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes. J Neurosci Res, 1998. 51(5): p. 563−73.
- Cristiano, L., A. Bernardo, and M.P. Ceru, Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes. JNeurocytol, 2001. 30(8): p. 671−83.
- Woods, J. W., et al., Localization of PPARdelta in murine central nervous system: expression in oligodendrocytes and neurons. Brain Res, 2003. 975(1−2): p. 10−21.
- Benani, A., et al., Evidence for the presence of both peroxisome proliferator-activated receptors alpha and beta in the rat spinal cord. J Chem Neuroanat, 2003. 25(1): p. 29−38.
- Cristiano, L., et al., Peroxisome proliferator-activated receptors (PPARs) and related transcription factors in differentiating astrocyte cultures. Neuroscience, 2005. 131(3): p. 577−87.
- Pahan, K., et al., Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem, 2002. 277(48): p. 45 984−91.
- Xu, J. and P.D. Drew, Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J Immunol, 2007.178(3): p. 1904−13.
- Xu, J., et al., Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol, 2006.176(1−2): p. 95−105.
- Defaux, A., et al., Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination. J Neuroinflammation, 2009. 6: p. 15.
- Kitamura, Y., et al., Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neurosci Lett, 1999. 262(2): p. 129−32.
- Syapin, P.J., Regulation ofhaeme oxygenase-1 for treatment of neuroinflammation and brain disorders. Br J Pharmacol, 2008. 155(5): p. 623−40.
- Chattopadhyay, N., et al., Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J Neurosci Res, 2000. 61(1): p. 67−74.
- Fitch, M.T., et al., Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J Neurosci, 1999. 19(19): p. 8182−98.
- Непека, M.T., et al., Focal glial activation coincides with increasedBACE1 activation and precedes amyloid plaque deposition in APP/Y7171. transgenic mice. J Neuroinflammation, 2005. 2: p. 22.
- Park, E.J., et al., 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) andSOCS3 in glia. J Biol Chem, 2003. 278(17): p. 14 747−52.
- Dello Russo, C., et al., Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem, 2003. 278(8): p. 5828−36.
- Spagnolo, A., et al., Differential effects of PPARgamma agonists on the metabolic properties of gliomas and astrocytes. Neurosci Lett, 2007. 417(1): p. 72−7.
- Petrova, T.V., K.T. Akama, and L J. Van Eldik, Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Deltal2,14-prostaglandin J2. Proc Natl Acad Sci USA, 1999. 96(8): p. 4668−73.
- Storer, P.D., et al., Cyclopentenone prostaglandins PGA2 and 15-deoxy-deltal2,14 PGJ2 suppress activation of murine microglia and astrocytes: implications for multiple sclerosis. J Neurosci Res, 2005. 80(1): p. 66−74.
- Perez-Ortiz, J.M., et al., Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem, 2004. 279(10): p. 8976−85.
- Luna-Medina, R., et al., Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem, 2005. 280(22): p. 2 145 362.
- Gurley, C., et al., Microglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR-gamma Agonists. PPAR Res, 2008. 2008: p. 453 120.
- Romera, C., et al., Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J Cereb Blood Flow Metab, 2007. 27(7): p. 1327−38.
- Klotz, L., et al., Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons. J Neurochem, 2003. 86(4): p. 907−16.
- Chawla, A., et al., PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med, 2001. 7(1): p. 48−52.
- Wohlfert, E.A., et al., Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol, 2007.178(7): p. 4129−35.
- Shi, Y., M. Hon, and R.M. Evans, The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA, 2002. 99(5): p. 2613−8.
- Herschman, H.R., Prostaglandin synthase 2. Biochim Biophys Acta, 1996. 1299(1): p. 125−40.
- Schwab, J.M., K. Seid, and H.J. Schluesener, Traumatic brain injury induces prolonged accumulation of cyclooxygenase-1 expressing microglia/brain macrophages in rats. J Neurotrauma, 2001.18(9): p. 88 190.
- Gottlicher, M., et al., Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A, 1992. 89(10): p. 4653−7.
- Kliewer, S.A., et al., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA, 1997. 94(9): p. 4318−23.
- Zhao, Y., et al., Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J, 2006. 20(8): p. 1162−75.
- Pontsler, A.V., et al., Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem, 2002. 277(15): p. 13 029−36.
- Zhao, X., et al., Distinct patterns of intracerebral hemorrhage-induced alterations in NF-kappaB subunit, iNOS, and COX-2 expression. J Neurochem, 2007.101(3): p. 652−63.
- Seimandi, M., et al., Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem, 2005. 344(1): p. 8−15.
- Chene, G., et al., n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaTcells. Biochim Biophys Acta, 2007.1771(5): p. 576−89.
- Каратассо, Ю.О., et al., Количественный анализ простагландинов и полиненасыщенных жирных кислот методом масс-спектрометрии с ионизацией электрораспылением. Масс-Спектрометрия, 2007. 4(3): р. 173−178.
- Heales, S J., et al., Neurodegeneration or neuroprotection: the pivotal role of astrocytes. Neurochem Res, 2004. 29(3): p. 513−9.
- Saluja, I., J.G. Granneman, and R.P. Skoff, PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia, 2001. 33(3): p. 191 204.
- Serhan, C.N., et al., Resolvins: a family ofbioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med, 2002. 196(8): p. 1025−37.
- Farooqui, A.A., et al., Phospholipase A2 and its role in brain tissue. J Neurochem, 1997. 69(3): p. 889−901.